10-K/A: Citius Pharma Amends 10-K for Governance, Compensation Details

Citius Pharmaceuticals, Inc. filed an amendment to its annual report to include detailed information on executive compensation, corporate governance, and related party transactions for the fiscal year ended September 30, 2025.

Summary

• This Amendment No. 1 to the Annual Report on Form 10-K for the fiscal year ended September 30, 2025, was filed to provide information required by Items 10, 11, 12, 13, and 14 of Part III, which were previously omitted from the Original Filing on December 23, 2025.
• The amendment includes updated certifications from the Principal Executive Officer and Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
• No financial statements or amendments to Items 307 and 308 of Regulation S-K are included in this amendment, nor are Section 906 certifications.
• The filing details the company's directors, executive officers, and corporate governance structure as of December 23, 2025.
• Executive compensation for Named Executive Officers (Leonard Mazur, Myron Holubiak, and Dr. Myron Czuczman) for fiscal years 2024 and 2025 is provided, including salaries, non-equity incentive plan compensation, option awards, and restricted stock units.
• Corporate goals for fiscal 2025 were met at 90% achievement, resulting in cash bonuses for executive officers: Leonard Mazur ($213,750), Myron Holubiak ($202,500), and Dr. Myron Czuczman ($141,750).
• Information on security ownership of certain beneficial owners and management as of December 31, 2025, indicates that all executive officers, directors, and director nominees as a group beneficially owned 4.99% of common stock.
• The company disclosed certain relationships and related transactions, primarily involving the extension of warrant terms held by Leonard Mazur and Myron Holubiak, which could generate approximately $9.5 million in cash proceeds if fully exercised.
• Fees paid to the independent registered public accounting firm, Wolf, for audit, audit-related, and tax services for fiscal years 2025 and 2024 are detailed.

Sentiment

Score: 6

Explanation: The filing is primarily administrative, addressing previously omitted information. While it shows good corporate governance practices in place and 90% achievement of corporate goals for executive bonuses, the late Form 4 filing by the CEO and the significant stock price movement around option grants (despite management's statement) introduce minor concerns. The potential for capital raise through warrant exercises is a positive for liquidity.

Positives

• Corporate goals for fiscal 2025 were met at 90% achievement, leading to cash bonuses for executive officers.
• The company has adopted a written Code of Ethics and Business Conduct, a corporate communications policy, and an insider trading policy to promote compliance and ethical conduct.
• The Audit and Risk Committee members satisfy the independence requirements of Nasdaq Listing Rules and SEC Rule 10A-3.
• Messrs. McGrath and Dutia are designated as audit committee financial experts, enhancing financial oversight.
• All directors, except the Chief Executive Officer and Executive Vice Chairman, are independent within the meaning of applicable Nasdaq listing standards.

Negatives

• Leonard Mazur, the Chief Executive Officer, filed a Form 4 on September 23, 2025, which was due on August 12, 2025, indicating a delay in reporting.
• Stock options granted to Named Executive Officers on November 7, 2024, had an exercise price of $9.50, and the closing market price of the securities underlying the award changed by 32% between the trading day immediately prior to and immediately following the disclosure of material nonpublic information.

Risks

• The filing is an amendment to correct omissions from the original 10-K, which could indicate prior administrative oversight or potential for future compliance issues.
• The 32% change in stock price around the grant date of executive stock options, despite management's statement about not timing releases, could raise questions about information asymmetry or market perception.
• The company relies on stock options for a greater portion of total compensation due to the early stage of most product candidates and a desire to preserve cash for their development, which implies potential cash flow constraints and reliance on equity for incentives.

Future Outlook

The company expects to continue using stock options as a primary long-term incentive vehicle, aligning executive interests with stockholders and supporting a pay-for-performance culture. This approach is also driven by the early stage of most product candidates and a desire to preserve cash for their development. The Compensation Committee or Board of Directors may consider adopting qualified or non-qualified benefit plans in the future.

Management Comments

• "We seek to achieve the following broad goals in our executive compensation programs and decisions regarding individual compensation: Attract and retain executives critical to our overall success. Reward executives for contributions to achieving strategic goals that enhance stockholder value. Foster and maintain a company culture of ownership, creativity and innovation. Motivate our executive officers to achieve critical longand short-term development, product and financial milestones set by the Board of Directors in consultation with management."
• "We believe that long-term corporate success is achieved with an ownership culture that encourages high performance by our employees through the use of stock-based awards."
• "We expect to continue to use stock options as a long-term incentive vehicle because: Stock options align the interests of our Named Executive Officers with those of our stockholders, supporting a pay-for performance culture, foster employee stock ownership, and focus the management team on increasing value for our stockholders. Stock options are performance-based. All of the value received by the recipient of a stock option is based on the growth of the stock price. In addition, stock options can be issued with vesting based on the achievement of specified milestones although we have not used such performance-based vesting to date. Stock options help provide balance to the overall executive compensation program as base salary and annual bonuses focus on short-term compensation, while stock options focus on long-term compensation. The vesting period of stock options over time encourages executive retention and is designed to increase stockholder value."
• "While we do not have a formal written policy in place with regard to the timing of awards of options or similar awards in relation to the disclosure of material nonpublic information, our equity awards are generally granted on fixed dates determined in advance. On limited occasions, our Compensation Committee or Board may grant equity awards outside of our annual grant cycle for new hires, promotions, recognition, retention or other purposes. The Committee approves all equity award grants on or before the grant date and does not grant equity awards in anticipation of the release of material nonpublic information. Similarly, the Committee does not time the release of material nonpublic information based on equity award grant dates."

Industry Context

This administrative filing provides insights into the corporate governance and executive compensation practices of Citius Pharmaceuticals, a company operating in the pharmaceutical and biotechnology sector. The emphasis on equity-based compensation and cash preservation reflects common strategies for early-stage biotech companies with long product development cycles. The mention of majority-owned subsidiaries, Citius Oncology and NoveCite, indicates a diversified approach within the life sciences industry.

Comparison to Industry Standards

• The company states that its executive benefits are comparable to benefit levels for comparable companies, though specific benchmarks are not provided.
• The use of stock options as a primary long-term incentive vehicle is a common practice in the biotechnology and pharmaceutical industry, where cash flow can be constrained during extensive research and development phases, and aligning management with long-term shareholder value is crucial.

Management Changes

Corporate Governance

Related Party Transactions

• On August 8, 2025, the company extended the term by one year to September 27, 2026, for 111,732 warrants with an exercise price of $19.25 per share, held by Leonard Mazur (CEO) and Myron Holubiak (Executive Vice Chairman). They participated in the original 2019 offering on the same basis as other investors.
• Additionally, 7,774 underwriter warrants with an exercise price of $27.97 per share from the 2019 offering were extended by one year to September 27, 2026.
• In August 2024 and August 2025, the company extended the term by one year (to August 14, 2025 and August 14, 2026, respectively) for 156,863 warrants with an exercise price of $28.75 per share, held by Mr. Mazur and Mr. Holubiak from the 2018 private placement. They participated on the same basis as other investors.
• Additionally, 7,576 placement agent warrants with an exercise price of $39.84 per share from the 2018 offering were extended in one-year increments to August 8, 2026.
• On April 3, 2024, the company extended the term by one year to April 5, 2025, for 51,780 warrants with an exercise price of $35.50 per share, held by Mr. Mazur and Mr. Holubiak from an April 2019 registered direct offering. They participated on the same basis as other investors. These warrants expired on April 5, 2025.
• Additionally, 9,605 placement agent warrants with an exercise price of $48.28 per share from the April 2019 offering were extended by one year to April 5, 2025. These warrants also expired on April 5, 2025.

Stakeholder Impact

• Shareholders: Impacted by the detailed executive compensation structure, potential dilution from warrant exercises, and the overall corporate governance framework. The late Form 4 filing by the CEO could be a minor concern for transparency.
• Employees: Benefit from stock-based awards and general compensation programs designed to attract and retain talent, fostering an ownership culture.
• Management: Compensation is tied to corporate goals and stock performance, aligning their interests with long-term company value.
• Regulatory Authorities: The filing addresses SEC disclosure requirements, and the late Form 4 filing is a compliance matter that has been disclosed.

Next Steps

• The company intends to post on its website all disclosures required by law or Nasdaq listing standards concerning any amendments to, or waivers from, any provision of the Code of Ethics.
• The Compensation Committee or Board of Directors may elect to adopt qualified or non-qualified benefit plans in the future.
• The Compensation Committee or Board of Directors may elect to provide officers and other employees with non-qualified defined contribution or other non-qualified deferred compensation benefits in the future.
• The company expects to continue to use stock options as a long-term incentive vehicle.

Key Dates

Recommendation

This filing is an administrative amendment to provide previously omitted corporate governance and executive compensation details. It does not contain new material financial or operational information that would significantly alter the investment thesis. The company's stated commitment to aligning executive interests with shareholders through equity and the achievement of 90% of corporate goals for bonuses are positive, but the late Form 4 filing by the CEO and the significant stock price movement around option grants (despite the company's explanation) introduce minor governance concerns. The potential for capital raise through warrant exercises is noted. Overall, the filing reinforces a "hold" position as it provides transparency on internal structures without presenting new catalysts for significant price movement.

Keywords

Citius Pharmaceuticals, SEC Filing, 10-K/A, Corporate Governance, Executive Compensation, Related Party Transactions, Biotechnology, Pharmaceuticals, Stock Options, Warrants